Pharmacokinetics of a novel anti-platelet drug from the glycoprotein IIb/IIIa receptor inhibitors group

Relevance. As part of the conducted open non-randomized phase I clinical trial the pharmacokinetics (PK) of the first Russian novel antiplatelet agent Angipur (nonpeptide glycoprotein IIb/IIIa receptor inhibitor) was studied.

Aim of the research was to evaluate PK parameters of Angipur in healthy volunteers after single dose ascending infusions.

Methods. 20 male healthy volunteers were enrolled in this phase I trial. Angipur (0.02% concentrate solution for infusion) was administered to every subject in single doses 0.015, 0.05, 0.09 mg/kg for 3 consecutive days. PK parameters were evaluated.

Results. After single intravenous administration of doses 0.015, 0.05, 0.09 mg/kg to healthy volunteers the peak plasma concentration of Angipur was reached at the end of the infusion, and then the plasma concentration rapidly decreased 15 minutes after the end of the infusion followed by slow decrease for 12 hours. Dose proportionality for key PK parameters was established. After single infusions of doses 0.015, 0.05, 0.09 mg/kg mean AUC_0-t was 27.11, 92.04 and 180.39 ng× h/ml; mean AUC_0-¥ – 37.03, 125.76 and 239.61 ng×h/ml; mean С_max – 12.44, 46.1 and 92.48 ng/ml; mean V_d – 304.01, 299.67 and 252.96 l; mean Т_1/2 – 6.72, 6.84 and 6.06 h; Сl – 32.19, 32.29 and 31.55 l/h; k_el – 0.1073, 0.1109 and 0.1257 l/h; MRT – 8.94, 8.93 and 8.18 h.

Conclusion. Pharmacokinetics of Angipur in studied doses demonstrated linearity, rapid reaching of С_max immediately after the infusion and the high distribution of the drug in tissues and biological fluids of the human organism..

1. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010 Feb;9(2):154–169. DOI: 10.1038/nrd2957.

2. Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1;39(9):763–816. DOI: 10.1093/eurheartj/ehx095.

3. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315–2381. DOI: 10.1093/eurheartj/ehw106.

4. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241.

5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115–126. DOI: 10.1056/NEJM199901143400207

6. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–325. DOI: 10.1038/nature10146

7. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1-e88. DOI: 10.1093/ejcts/ezw313

8. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. DOI: 10.1093/eurheartj/ehv320

9. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. DOI: 10.1093/eurheartj/ehx393

10. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2018 Jan 1;53(1):34–78. DOI: 10.1093/ejcts/ezx334.

11. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104(6):1606–1615. DOI: 10.1182/blood-2004-04-1257.

12. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995;76(17):1222– 1227. DOI: 10.1016/s0002-9149(99)80345-2

13. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, King LW, Miyano M, et al. In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent. Thromb Res. 1991;62(5):567–578. DOI: 10.1016/0049-3848(91)90029-v

14. Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/ IIIa antagonist, is active in man. Circulation. 1993;88(4 Pt 1):1512–1517. DOI: 10.1161/01.cir.88.4.1512

15. Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian lamifiban study. Circulation. 1996;94(5):899–905. DOI: 10.1161/01.cir.94.5.899

16. Tereshchenko AS, Merkulov EV, Samko AN. Glycoprotein IIb/IIIa Receptor Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention. Rational Pharmacotherapy in Cardiology. 2019;15(6):918–927. (In Russ).]. DOI: 10.20996/1819-6446-2019-15-6-918-927

17. Tscharre M, Michelson AD, Gremmel T. Novel Antiplatelet Agents in Cardiovascular Disease. J Cardiovasc Pharmacol Ther. 2020;25(3):191–200. DOI: 10.1177/1074248419899314.

18. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010;9(5):801–819. DOI: 10.1517/14740338.2010.507189.

19. King S, Short M, Harmon C. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban. Vascul Pharmacol. 2016;78:10–16. DOI: 10.1016/j.vph.2015.07.008.

20. Smirnova LA, Spasov AA, Khaliullin FA, Kucheryavenko AF, Ryabukha AF, Abramov OK. Biopharmaceutical study of an injectable dosage form of the new antiaggregant substance 3-methyl-8-(piperazin-1-yl)-7-(thietan-3-yl)-1-ethyl-1H-purine-2,6(3H,7H)-dione hydrochloride. Khimiko-Farmatsevticheskii Zhurnal. 2021;55(1):14–16. (In Russ).]. DOI: 10.30906/0023-1134-2021-55-1-16-18.

21. Smirnova LA, Ryabukha AF, Abramov OK, Kucheryavenko AF, Spasov AA, Khaliullin FA. Quantitative determination of angipur substance in plasma by HPLC with fluorescence detection. Khimiko-Farmatsevticheskii Zhurnal. 2021;55(2):60–64. (In Russ).]. DOI: 10.30906/0023-1134-2021-55-2-60-64.

22. Rukovodstva i metodicheskie rekomendacii. Rukovodstvo po provedeniyu klinicheskih issledovanij lekarstvennyh sredstv. CHast' pervaya / Ed by A.N. Mironov. Moscow: Grif i K, 2013. (In Russ).].

23. Mironov AN, Petrov VI, Merkulov VA, Bupyatyan ND, Sakaeva IV, Kukes VG, et al. NTP. Rukovodstva i metodicheskie rekomendacii. Rukovodstvo po ekspertize lekarstvennyh sredstv. Tom I. Moscow: Grif i K, 2019. (In Russ).].

24. Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation [Интернет]. London: European Medicines Agency; 2012 [цитируется по 21 январь 2022 г.]. 23 с. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf

25. NTP. Rukovodstva i metodicheskie rekomendacii. Rukovodstvo po provedeniyu klinicheskih issledovanij lekarstvennyh sredstv (immunobiologicheskie lekarstvennye preparaty). CHast' vtoraya /Ed by A.N. Mironova. Moscow: Grif i K, 2013. (In Russ).].

26. Mironov AN, Merkulov VA, Bupyatyan ND, Sakaeva IV, Kukes VG, Medunitsyn NV, et al. NTP. Rukovodstva i metodicheskie rekomendacii. Rukovodstvo po ekspertize lekarstvennyh sredstv. Tom II. Moscow: Grif i K, 2019. (In Russ).].

27. Mironov AN, Merkulov VA, Bupyatyan ND, Sakaeva IV, Kukes VG, Medunitsyn NV, et al. NTP. Rukovodstva i metodicheskie rekomendacii. Rukovodstvo po ekspertize lekarstvennyh sredstv. Tom III. Moscow: POLIGRAF-PLYUS, 2014. (In Russ).

28. Mironov AN, Merkulov VA, Sakaeva IV, Kukes VG, Meduniyin NV, Lepakhin VK, et al. NTP. Rukovodstva i metodicheskie rekomendacii. Rukovodstvo po ekspertize lekarstvennyh sredstv. Tom IV. Moscow: POLIGRAF-PLYUS, 2014. (In Russ).

29. Belousov YuB, Gurevich KG. Obshchaya i chastnaya klinicheskaya farmakokinetika. Moscow: OOO «Informacionno-izdatel'skoe agentstvo «Remedium». 2006. (In Russ).

30. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278–1283. DOI: 10.1023/a:1026451721686

31. Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8(1):38–49. DOI: 10.1002/pst.326

32. Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet. 2002;41(3):187–195. DOI: 10.2165/00003088-200241030-00003

33. № 02/19-ELTA «Mnogocentrovoe randomizirovannoe prostoe slepoe klinicheskoe issledovanie rezhima dozirovaniya, effektivnosti i bezopasnosti preparata Angipur (koncentrat dlya prigotovleniya rastvora dlya infuzij 0,02 %) v sravnenii s preparatom eptifibatid (rastvor dlya vnutrivennogo vvedeniya) u bol'nyh s ostrym koronarnym sindromom s pod"yomom segmenta ST EKG pri chreskozhnoj translyuminal'noj koronarnoj angioplastike vysokogo riska so stentirovaniem». [Internet]. (In Russ). URL: https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=762c3c7b-5576-4f01-a0ae-bee787d76d05&CIPermGUID=8E940830-13CC-43F7-8310-BF3CD867D20F